Dr. Sequist Discusses the Efficacy of CO-1686 for NSCLC

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the efficacy of CO-1686 for the treatment of non-small cell lung cancer (NSCLC).

It has been known for 10 years that EGFR mutations define a group of patients that respond well to EGFR TKIs. These patients, though, often face resistance due to an acquired T790M mutation that occurs after about a year of treatment. This has been a vexing problem, Sequist says.

Now, researchers and oncologists are seeing activity in this setting with several agents. In an ongoing phase I trial presented at the 2014 ASCO Annual Meeting, it was reported that a number of patients responded to CO-1686. In this study, 58% of patients experienced an overall response across all dose levels.